GSK CEO Dame Emma Walmsley took home £8.45 million ($10.2 million) in 2022, the British pharma giant announced this week. 

Walmsley, who has been CEO of GSK since 2017 and previously served on the board of directors since 2011, received a total fixed pay of £1.6 million and £6.8 in total pay for performance. Her total remuneration is up from £8.2 million in 2021. 

In addition to Walmsley, outgoing GSK CFO Iain Mackay received £5.3 million in total remuneration while former chief scientific officer Dr. Hal Barron received £7.1 million until he transitioned from his role to non-executive director in August.

The company also paid Walmsley a £3.1 million bonus in 2022 while Mackay received a total bonus of just over £2 million. 

Mackay is slated to step down from his role as CFO this spring, at which point he will be replaced by Julie Brown, GSK’s first female CFO, who is currently the COO and CFO at Burberry Group. GSK said that Mackay will continue to receive his base salary until he leaves the company at the end of this year and will be eligible to receive an annual bonus.

Brown’s salary was preliminarily set at £915,335 to match Mackay’s pay, but was subsequently bumped up 4% to £951,948.

Though Walmsley’s pay makes her one of the U.K.’s most well-compensated executives, it pales in comparison to her peer, AbbVie CEO Richard Gonzalez, who received $26.2 million in total compensation last year.

Notably, Walmsley did make more than Novartis CEO Vas Narasimhan, who earned 8.4 million Swiss francs ($9 million) in 2022, marking a 25% decrease from the year prior.

Under Walmsley’s leadership, GSK enjoyed a strong 2022, recording sales of £29.3 billion, up 13% at constant exchange rates (CER), including £11.3 billion in specialty medicines, £10.1 billion in general medicines and £7.9 billion in vaccines. 

The drugmaker’s free cash flow totaled £3.3 billion, its total continuing earnings per share (EPS) rose 18% CER and its adjusted EPS increased 15% CER. 

In its most recent earnings statement, GSK said it expects its adjusted operating profit to increase between 10% to 12% in 2023.